Abbvie Inc Stock Price, News & Analysis

AbbVie announced promising Phase 2 CAPTIVATE study results for its investigational combination of IMBRUVICA® and VENCLEXTA® to treat previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The combination achieved a complete response (CR) rate of 56% among patients without del(17p), with a 24-month progression-free survival of 95% and overall survival of 98%. Undetectable minimal residual disease was observed in 77% of patients. Safety profiles aligned with known adverse effects, with no new signals identified.

AbbVie announced new long-term data from the Phase 3 RESONATE-2 study evaluating IMBRUVICA (ibrutinib) for chronic lymphocytic leukemia (CLL). Presenting at the ASCO Annual Meeting, results show sustained progression-free survival (PFS) and overall survival (OS) benefits with IMBRUVICA compared to chlorambucil over seven years. The study revealed a 61% PFS rate and 78% OS rate for IMBRUVICA. Additionally, data from the informCLL registry highlighted treatment alignment with NCCN guidelines, stressing the need for prognostic testing in high-risk patients for optimal therapy.

AbbVie (NYSE: ABBV) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021. The event will feature key executives including Michael Severino, Robert A. Michael, and Jeffrey R. Stewart, who will participate virtually at 8:40 a.m. Central time.

A live audio webcast will be available on AbbVie's Investor Relations website, with an archived version to follow later that day.

AbbVie aims to deliver innovative medicines across multiple therapeutic areas, enhancing lives and addressing future medical challenges.

AbbVie announced positive top-line results from the Phase 3 FORTIFY study, demonstrating that risankizumab 360 mg achieved significant endoscopic response and clinical remission in adult patients with moderate to severe Crohn's disease after one year. Key results included 47% achieving endoscopic response and 52% achieving clinical remission, compared to only 22% and 41% in the control group, respectively. Risankizumab 180 mg also met co-primary endpoints in the U.S. analysis. No new safety risks were identified, maintaining a consistent safety profile. Full results will be presented at future conferences.

AbbVie (NYSE: ABBV) has released positive results from the Phase 3 SELECT-PsA 2 clinical trial of RINVOQ® (upadacitinib, 15 mg, once daily), showing sustained improvements in active psoriatic arthritis for over one year. At week 56, 29% of patients achieved minimal disease activity, and 60% achieved ACR20 response. The study also reported improvements in skin clearance and no new significant safety issues. These results highlight RINVOQ's potential in managing psoriatic arthritis symptoms long-term, supporting its recent EU approval for this indication.

AbbVie announced new data presented at EULAR 2021, showing RINVOQ (upadacitinib) 15 mg leads to higher rates of clinical remission and low disease activity in moderate to severe rheumatoid arthritis patients compared to HUMIRA (adalimumab) over three years. Clinical remission was achieved in 32% of RINVOQ patients versus 22% with HUMIRA. The safety profile of RINVOQ remained consistent over 4.5 years, with no new risks identified. Overall, this data reinforces the efficacy and safety of RINVOQ as a treatment option.

AbbVie (NYSE: ABBV) will participate in Bernstein's 37th Annual Strategic Decisions Conference on June 2, 2021, at 2:30 p.m. Central Time. Presenters will include Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and CFO. A live audio webcast will be available on AbbVie's Investor Relations website, with an archived edition posted later the same day. AbbVie is committed to developing innovative medicines across various therapeutic areas, including immunology, oncology, and neurology.

AbbVie (NYSE: ABBV) will present key data from its migraine portfolio at the 2021 American Headache Society Annual Scientific Meeting, scheduled for June 3-6. A total of 23 abstracts, including four podium presentations, will cover significant findings on preventive and acute migraine treatments, highlighting atogepant and UBRELVY®. Dr. Mitchell Mathis emphasized the importance of these advancements in addressing the debilitating impact of migraines on millions. Presentations will include studies on treatment gaps, efficacy, and patient quality of life, showcasing AbbVie's commitment to the migraine community.

AbbVie (NYSE: ABBV) has received European Commission approval for VENCLYXTO (venetoclax) in combination with hypomethylating agents azacitidine or decitabine. This treatment is aimed at adult patients with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. The approval applies to all 27 EU member states, Iceland, Liechtenstein, and Norway. Clinical trials indicate that this combination improves overall survival compared to azacitidine alone, marking a significant advancement in AML treatment options.